Results from a phase 2a study suggest that the benefits of Tezspire (tezepelumab) for people with chronic pulmonary obstructive disease may be limited to those with elevated blood eosinophil counts indicative of type 2 inflammation. #ATS2024 managedhealthcareexecutive.com/view/tezspire-…